Disclosed is the use of a dopamine receptor D2 inhibitor medicament for treating depression improving cognition and/or treating other syndromes conditions or diseases for which anti-depressant agents are prescribed. The dopamine receptor D2 inhibitor medicament is formulated for administration in an administration cycle the administration cycle comprising: i. administering the D2 receptor inhibitor to elevate amounts of the D2 receptor's high affinity state inducing dopamine receptor supersensit...

A method for treating coronavirus infection by administering to a subject in need of the treatment an effective amount of one or more of the following compounds: aklavin sanguinarine amiodarone chlorpromazine clomiphene dihydroergotamine dipyridamole emetine ephedrine prochlorperazine promazine propiomazine aminacrine fluphenazine fenoterol peruvoside proglumide atenolol nerifolin nefopam cycloheximide avermectin B1 bepridil cinnarizine ethisterone pararosaniline methylbenzethonium niclosamide p...

1. A composition comprising (S)-2-(benzylamino-methyl)-2389-tetrhydro-7H-14-dioxino [23-e] indol-8-one and an antipsychotic agent. 2. A pharmaceutical composition comprising (S)-2-(benzylaminomethyl)-2389-tetrahydro-7H-14-dioxino [23-e] indol-8-one an antipsychotic agent and one or more pharmaceutical carriers therefor. 3. A pharmaceutical composition for treating a patient suffering from a psychotic disorder comprising an effective amount of (S)-2-(benzylamino-methyl)-2389-tetrahydro-7H-14-diox...

A composition comprising (S)-2-(benzylamino-methyl)-2389-tetra-hydro-7H-14-dioxino[23-e]indol-8-one and an antipsychotic agent. The antipsychotic agent may be selected from chlorpromazine mesoridazine thioridazine fluphenzine trifluoperazine perphenzine clozapine haloperidol loxapine molindone thiothixene risperidone quetiapine and olanzapine.

1. A pharmaceutical formulation which comprises in addition to at least one carrier diluent or adjuvant at least one neuroleptic compound in an amount effective to exert a neuroleptic effect in a patient requiring such treatment and melatonin in an amount effective to ameliorate or prevent symptoms of tardive dyskensia developing in the patient. 2. A pharmaceutical formulation according to claim 1 characterized by at least one of the following features: it is adapted for oral rectal parenteral o...

The invention provides methods for inhibiting psychostimulant-induced or nicotine-induced craving of additional psychostimulants (e.g. cocaine or amphetamine) or nicotine. In these methods D1-like (dopamine receptor) antagonists or agonists selected from the group consisting of SCH-39166 SCH-23388 SCH-23390 A-69024 bulbocapnine (+)butaclamol HCI fluphenazine HCI cis-(Z)-flupenthixol fluspirilene haloperidol SCH-12679 SKF-83566 thioridazine HCI thiothixene HCI trifluoperazine 2HCI trifluperidol H...